西南医科大学学报2024，Vol.47Issue(4)：289-294,6.DOI:10.3969/j.issn.2096-3351.2024.04.003
视神经脊髓炎谱系疾病生物靶向治疗研究进展
Research progress on biological targeted therapy for neuromyelitis optica spectrum disorder
张梦洁 1秦新月1
作者信息
- 1. 重庆医科大学附属第一医院神经内科(重庆 400010)
- 折叠
摘要
Abstract
Neuromyelitis optica spectrum disorder(NMOSD)is an autoimmune,inflammatory demyelinating disease of the cen-tral nervous system,primarily affecting the optic nerves and spinal cord.It is characterized by high relapse rates and significant disabil-ity,severely impacting patients'quality of life.Sequential therapy plays a crucial role in the management of NMOSD.In recent years,biological therapies have demonstrated superior efficacy compared to traditional immunosuppressants in treating NMOSD.Aiming to provide reference and guidance for the biotargeted treatment of NMOSD,this article reviewed three types of biological agents which have been approved globally for the treatment of NMOSD,including complement inhibitors,IL-6 receptor blockers,and B lymphocyte depleting agents.关键词
视神经脊髓炎谱系疾病/生物靶向治疗/免疫治疗/自身免疫性脱髓鞘疾病Key words
Neuromyelitis optica spectrum disorder/Biological targeted therapy/Immunotherapy/Autoimmune demyelinating disease分类
医药卫生引用本文复制引用
张梦洁,秦新月..视神经脊髓炎谱系疾病生物靶向治疗研究进展[J].西南医科大学学报,2024,47(4):289-294,6.
